Advertisements

Bisocor 10 mg

Quick links to important sections

Bisocor 10 mg

Advertisements
Advertisements

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Bisocor 10 mg

What is Bisocor 10 mg? (Overview)

Property Description
Active ingredient Bisoprolol fumarate
Form Oral tablet (film-coated)
Pharmacological class beta1-selective beta-blocker
Common use Management of high blood pressure
Regulatory Status Prescription-only (Rx)

Bisocor 10 mg is a specific prescription formulation containing the active substance bisoprolol fumarate at a strength of 10 milligrams (mg) per tablet. Bisoprolol is classified as a beta1-selective adrenoceptor blocking agent, commonly referred to as a beta-blocker. This specific selectivity is a key feature, as it means the drug preferentially targets the beta1 receptors in the heart.

Its primary function is to block the effects of stress hormones, like adrenaline (epinephrine), on the heart. By doing so, it reduces the heart's rate and the force of its contractions, actions that are clinically recognized for lowering blood pressure and decreasing the overall workload on the heart muscle. The 10 mg strength is one of the concentrations used in the continuation phase of therapy after lower dosages have been established.

The synthetic bisoprolol compound is globally recognized for its importance. The substance is listed as an essential medicine for its role as an antianginal and antihypertensive agent, confirming its established medical value. Bisocor 10 mg is an Rx (prescription-only) medicine intended for daily, long-term use under the direct supervision of a healthcare provider.

Regulatory References

  1. WHO Essential Medicines List for Bisoprolol
Advertisements

What side effects are possible with Bisocor 10 mg?

Official Safety Profile of Bisocor 10 mg

Regulatory documentation classifies the possible adverse effects of Bisocor 10 mg (bisoprolol fumarate) based on the body systems affected and their expected frequency of occurrence. The majority of documented side effects are typically observed early in treatment and are often transient.

Frequency-Classified Adverse Reactions

Adverse reactions are grouped by official regulatory frequency categories:

  • Very Common: Bradycardia (slowed heart rate), particularly noted in patients receiving treatment for chronic heart failure.
  • Common: General feelings of fatigue, dizziness, and headache, which are frequently experienced at the start of treatment. Common effects also include coldness or numbness in the extremities and gastrointestinal disturbances such as nausea, vomiting, diarrhea, or constipation.
  • Uncommon: Disturbances of the heart's electrical conduction (atrioventricular block), worsening of pre-existing heart failure, muscle cramps, and depression are listed as uncommon reactions.

Serious Adverse Reactions and Safety Constraints

Official labels highlight clinically significant safety concerns. Serious adverse reactions include the deterioration of existing heart failure and the occurrence of significant disturbances to atrioventricular conduction. For individuals with certain pre-existing respiratory conditions, bronchospasm is a documented risk.

Safety notes specify constraints for specific patient populations. Bisoprolol may mask symptoms of hypoglycemia in patients with diabetes mellitus and can potentially aggravate psoriasis. Furthermore, regulatory documentation explicitly states that treatment must not be stopped abruptly, especially in patients with coronary heart disease, due to the potential for symptom exacerbation.

Advertisements

Overdose and Emergency Response

Overdose and when to seek help

An overdose of Bisocor 10 mg (bisoprolol fumarate) is officially classified as a condition requiring immediate medical attention. The official regulatory profile is defined by severe manifestations of profound cardiovascular depression.

Documented Manifestations

Overdose is formally documented to present with severe manifestations, including abnormally slow heart rate (bradycardia) and low blood pressure (hypotension). Other documented signs involve systemic effects such as dangerously low blood sugar (hypoglycaemia), difficulty breathing (bronchospasm), lethargy, and dizziness. Potential life-threatening outcomes include the risk of acute cardiac failure, seizures, and coma.

Required Emergency Actions

Regulatory documents mandate that you seek immediate medical attention for any suspected overdose. Emergency services must be contacted immediately if the affected person collapses, has trouble breathing, or cannot be awakened. Management is defined as symptomatic and supportive treatment, as no specific antidote is known. Procedures described include the administration of agents like intravenous Atropine or Glucagon to manage severe cardiac effects. Hospitalization and continuous cardiac monitoring are required for close observation. Special attention is documented for patients with diabetes due to the risk of masked hypoglycaemia and for patients with asthma due to the risk of severe bronchospasm.

Advertisements

Therapeutic Uses of Bisocor 10 mg

The primary therapeutic uses and benefits of Bisocor 10 mg (bisoprolol fumarate) span several critical cardiovascular domains, and may assist with supportive management for symptoms and systemic risk. The medication is generally used for long-term control of several conditions.

The medication is commonly used to help manage chronic conditions characterized by systemic imbalance, including essential hypertension (high blood pressure), chronic stable angina pectoris (exertion-related chest discomfort), and stable chronic heart failure. It is also applied across domains where additional symptomatic support is needed to control symptoms related to heightened physiological activity, such as the rapid or irregular heart rate seen in atrial fibrillation.

“Its application is relevant when supportive symptom management is appropriate, assisting patients during episodes of heightened discomfort.”

A key therapeutic benefit for patients may be the supportive reduction in systemic pressure, which helps manage cardiovascular risk, alongside the support it provides in easing functional stress. Bisocor is applied in clinical settings that involve unstable symptom patterns, which may assist with maintaining functional stability when symptoms interfere with routine activities.


Quick Fact: Relief for Cardiac Overload Symptoms

The use of Bisocor 10 mg may help support day-to-day comfort by helping to address the symptom clusters associated with chronic stable angina and elevated heart rate.

Advertisements

Eligibility and Restrictions for Use

Who Can and Cannot Use Bisocor 10 mg?

Use of Bisocor 10 mg is restricted to the adult population and is explicitly prohibited under certain clinical conditions, as determined by regulatory labeling.

Absolute Contraindications (Must Not Use)

Bisocor 10 mg is contraindicated in patients with acute or severe untreated conditions, including:

  • Cardiogenic shock or overt cardiac failure (acute/decompensated).
  • Specific severe conduction blocks (second or third degree AV block) and marked sinus bradycardia (severe slow heart rate).
  • Severe bronchial asthma or severe obstructive pulmonary disease.
  • Metabolic acidosis or known hypersensitivity to the active substance.

Age and Organ Function Restrictions

  • Pediatric Use: Safety and efficacy have not been established in children and adolescents under 18 years of age, and use is not recommended.
  • Organ Impairment: Patients with severe renal or hepatic impairment have official restrictions, and the daily dose should not exceed 10 mg as per regulatory documentation.
  • Pregnancy/Lactation: Use during pregnancy is restricted and recommended only if clearly needed. Use during lactation requires caution.
Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory documentation identifies several categories of medicinal products that interact with Bisocor 10 mg (bisoprolol fumarate), primarily through additive pharmacological effects.

Interacting Medicinal Product Categories

Category Interaction Risk/Constraint
Other beta-blockers Co-administration is generally restricted due to the risk of additive cardiac depression.
Calcium Channel Blockers (e.g., verapamil, diltiazem) Increased risk of bradycardia and AV conduction issues, requiring close monitoring.
Antiarrhythmics (e.g., amiodarone, disopyramide) Increased risk of negative chronotropic and dromotropic effects on the heart.
Clonidine Requires specific withdrawal timing: bisoprolol must be discontinued several days before discontinuing clonidine.
Insulin and Oral Hypoglycemics Bisoprolol can mask the warning signs of acute hypoglycemia, such as rapid heart rate (tachycardia).
Rifampin Rifampin increases the metabolic clearance of bisoprolol, which may reduce its concentration in the body.
Catecholamine-depleting drugs (e.g., reserpine) Risk of additive effects, including excessive slowing of the heart rate (bradycardia).

These documented interactions structure the product's official profile by setting conditions for use or caution against specific combinations. Patients with a history of severe allergic reactions may be unresponsive to the usual dose of epinephrine due to bisoprolol's action.

Advertisements

Mechanism of Action

Selective Targeting of Adrenergic Receptors

The drug acts as a selective antagonist (blocker) on Beta-1 receptors (beta1 receptors) found predominantly on the heart's surface, interfering with specific signaling pathways. This action limits the binding and influence of stimulating hormones like adrenaline on the cardiac muscle cells.


Modulating Cardiac Rate and Contraction

By suppressing these key signaling sequences, the drug modifies early molecular steps, resulting in a reduction in the frequency and force of the heart's contractions. This mechanical effect results in a lower utilization of oxygen by the cardiac muscle.


Regulating Systemic Workload

This mechanism limits the stimulatory influence of the sympathetic nervous system on the heart's pathway activity. This systemic effect translates into a lowered cardiac output, a change within the circulatory system's hemodynamic parameters.

Advertisements

Dosage and Administration Information

How to Use Bisocor 10 mg

The administration of Bisocor 10 mg (bisoprolol fumarate) is governed by official prescribing information, which details the high-level procedural rules for dosing, frequency, and administration conditions. This information is designed to standardize its use across different clinical scenarios.

Official Administration Guidelines

Bisocor 10 mg is designated for oral use in the form of a film-coated tablet. The frequency for all approved indications is once daily (qDay), with an official recommendation to take the dose in the morning. The tablets may be taken with or without food and are generally intended to be swallowed whole with liquid.

Labeled Dosing and Procedural Requirements

For most patients managing hypertension or chronic stable angina, the 10 mg strength represents the usual daily maintenance dose, though the maximum recommended dose is 20 mg once daily.

Procedural Structure for Use

Feature Official Instruction Summary
Heart Failure Dosing Treatment requires a gradual, multi-week titration phase starting at 1.25 mg. The 10 mg strength is the maximum target dose.
Discontinuation Treatment must not be stopped abruptly. When ending therapy, the dose must be slowly and gradually reduced over time.
Special Populations A maximum dose of 10 mg once daily is specified for patients with severe renal or hepatic impairment.

The official protocol emphasizes a controlled approach: consistent once-daily intake, adherence to specific dose-adjustment schedules, and a mandatory slow reduction if the therapy is ever ceased. This structure defines the long-term, procedural use of the drug as established by medical guidelines.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Bisocor 10 mg

Evidence for Use in Chronic Stable Angina Pectoris

The research base for bisoprolol was studied in individuals experiencing chronic stable angina, supported by a structured body of evidence. This research has included both Randomized and crossover trials, as well as long-term observational studies that track patients over extended periods. Studies examined outcomes related to physical discomfort, specifically measuring the frequency of chest pain episodes reported by patients. Research also monitored changes in functional capacity, such as tracking how long subjects could exercise or walk before the onset of discomfort. Evidence contributes to understanding symptom patterns and the broader evidence landscape for this condition.

Evidence for Use in Essential Hypertension

The clinical evaluation of bisoprolol for the management of high blood pressure, or essential hypertension, largely consists of short-term randomized trials and prospective observational studies. Research examined outcomes like the measurement of blood pressure change (systolic and diastolic) and the patterns of change in the mean heart rate. Study results reflect the specific conditions under which they were conducted. However, a significant portion of the data is derived from studies that were observational or open-label. Therefore, evidence quality varies across studies, and follow-up durations were limited in many key trials.

Evidence for Use in Stable Chronic Heart Failure

The foundational evidence for using bisoprolol in stable chronic heart failure is derived from large-scale Randomized Controlled Trials (RCTs). These studies actively monitored major clinical events. The investigators focused on the most critical endpoints, including all-cause mortality and cardiovascular death, as well as the frequency of hospitalization for worsening heart failure. Research also examined changes in the heart's pumping function, tracked as the Left Ventricular Ejection Fraction (LVEF). Findings describe patterns observed in the populations studied concerning monitoring of mortality and hospitalization rates over follow-up periods that extended to several years.

What Remains Uncertain About the Research

Research provides context but not individual predictions, and the evidence highlights what is known—and what is still uncertain. The main gaps identified stem from the inherent limitations of study designs. For instance, long-term outcomes are not well characterized beyond the specific trial durations, and the evidence provides insight into group patterns, but research does not determine whether an individual with unique health issues will report similar outcomes to the trial groups.

Key Studies & References

  1. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial (Chronic Stable Heart Failure)
  2. WHO Model List of Essential Medicines - Bisoprolol (Regulatory/Guideline Context)
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Bisocor 10 mg (FAQ)


Q: How quickly can someone expect Bisocor 10 mg to start working?

According to official product information, the active substance typically reaches its highest level in the bloodstream within two to four hours after a tablet is taken. The maximum effects on heart rate and blood pressure may generally be observed within this early time frame post-dosing.


Q: Can Bisocor 10 mg cause weight gain?

Official safety documents indicate that 'weight changes' are a reported possible effect. This finding is noted in the context of other metabolic effects, though weight gain itself is not always explicitly detailed by frequency in all official regulatory labels.


Q: Is it common to feel dizzy when first starting Bisocor 10 mg?

Yes, regulatory documents list dizziness as a Common adverse reaction, meaning it is frequently observed in patients. This effect is often reported particularly during the initial phase of treatment or when the dose is being adjusted under medical guidance.


Q: What should be done if Bisocor 10 mg makes my hands or feet feel cold?

Feelings of coldness or numbness in the hands and feet are noted as a Common adverse effect in official safety profiles. Regulatory documentation indicates that these symptoms are part of the known adverse effect profile and are typically monitored during routine medical supervision.


Q: What is the difference between Bisocor 5 mg and Bisocor 10 mg?

The difference between the 5 mg and 10 mg tablets primarily relates to the dose level used in therapy. For conditions like hypertension and angina, the 5 mg dose often serves as a starting point, while 10 mg is designated as the usual daily maintenance dose for many patients. Both strengths are utilized within the controlled dose increase protocol for chronic stable heart failure.


Q: Why is 10 mg considered a high dose for this medicine?

The 10 mg strength is considered the usual therapeutic dose for several conditions. It is also the designated maximum recommended maintenance dose for certain patient groups, such as those with significant kidney or liver impairment, and it is the maximum target dose in the treatment of chronic stable heart failure.


Q: Can Bisocor 10 mg be taken on an empty stomach?

Official instructions confirm that Bisocor 10 mg tablets should be taken once daily in the morning and can be taken either with or without food.


Q: What does official guidance say about Bisocor 10 mg use while breastfeeding?

Official regulatory documentation states that use of the drug during the period of lactation requires caution. Available limited data indicates that low levels of the active substance may pass into breast milk.


Q: What happens if I miss a dose of Bisocor 10 mg?

Official patient information generally describes procedures for a missed dose, stating that it may be taken as soon as the patient remembers, unless it is nearly time for the next scheduled dose. It explicitly states that taking a double dose to compensate for a missed dose is not advised.


Q: How often do people report having trouble sleeping (insomnia) on Bisocor 10 mg?

Official safety data lists 'Insomnia' and other sleep disturbances as Uncommon adverse reactions in some regulatory labeling. This means they were reported to occur in clinical trials in a frequency range of between 0.1% and 1% of the population studied.


Q: Can Bisocor 10 mg be used with herbal supplements?

Regulatory sources generally note that the use of herbal remedies and supplements with prescription medicines requires attention from a healthcare provider. This is because these non-regulated products may not be tested for drug interactions in the same way as prescription medicines.


Q: Are there specific symptoms that require immediate medical attention while on Bisocor 10 mg?

Official safety labels highlight several serious adverse reactions. These concerns include the worsening of conditions such as heart failure, which can involve changes like swelling or difficulty breathing, as noted in the risk information.


Q: Does Bisocor 10 mg have a generic version available?

Yes, the active ingredient in Bisocor 10 mg, which is bisoprolol fumarate, is widely available in a generic version approved by various international regulatory agencies. The generic form contains the same active substance.


Q: Can Bisocor 10 mg be split in half?

Official documentation for certain formulations of bisoprolol tablets confirms that the tablet is scored with a break line, which allows it to be divided into two equal halves. The ability to split the tablet is formulation-specific and should be confirmed by checking the packaging or patient information leaflet.


Q: Why are people told to taper off Bisocor 10 mg instead of stopping abruptly?

Official guidelines require a slow reduction because abrupt discontinuation carries a documented risk of acute worsening of the underlying condition. This risk is a particular concern for patients with underlying coronary heart disease.


Advertisements

How should Bisocor 10 mg be stored and disposed of?

How to Store and Dispose of Bisocor 10 mg

Bisocor (bisoprolol fumarate) 10 mg tablets must be stored according to official regulatory specifications to maintain product quality.

Storage Requirements

The tablets should be kept out of the sight and reach of children. The medicine must be stored below 30 C or at or below 25 C, depending on the specific formulation. It must be kept in the original container, which should be closed, and must be protected from light and moisture. The product should not be used past the expiry date stated on the packaging. For product stability in bottle packaging, the tablets should be used within six months after opening.


Disposal Instructions

Regulatory instructions state that the medicine must not be thrown away with household waste or wastewater. Individuals must ask a pharmacist how to correctly dispose of unused or expired Bisocor tablets to ensure compliance with local pharmaceutical waste requirements.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Bisocor 10 mg found in:

A-Z Index: